Aberdeen Asset Management PLC (ADN.L)
|Market Cap (Mil.):||£5,244.07|
|Shares Outstanding (Mil.):||1,314.30|
* Assets under management 331.2 billion pounds at end-Aug.
LONDON, Sept 29 - Aberdeen Asset Management said assets under management rose 3 percent to 331.2 billion pounds ($537.60 billion) at end-August, boosted by performance and favourable foreign exchange moves, and a slowdown in the pace of outflows.
SINGAPORE - Aberdeen Asset Management PLC said on Friday its Asian unit has been given a Renminbi Qualified Foreign Institutional Investor license (RQFII) and plans to launch a China A share investment fund.
SINGAPORE, Sept 26 - Aberdeen Asset Management PLC said on Friday its Asian unit has been given a Renminbi Qualified Foreign Institutional Investor licence (RQFII) and plans to launch a China A share investment fund.
JAKARTA, Sept 22 - British firm Aberdeen Asset Management PLC's Asian arm has obtained regulatory approval to buy 80 percent of Indonesia's PT NISP Asset Management, a person with direct knowledge of the matter said on Monday.
June 25 - Aberdeen Asset Management Plc said it appointed Korawut Leenabanchong chief executive officer for its Thailand operations.
MONACO, June 24 - British fund manager Aberdeen Asset Management Plc sees greater than forecast savings from its recent SWIP acquisition and expects to raise its dividend this year, as well as seeing scope to buy back shares, its chief executive said on Tuesday.
(The following statement was released by the rating agency) LONDON, June 18 (Fitch) Fitch Ratings has affirmed Aberdeen Asset Management Plc's (AAM) Long-term Issuer Default Rating (IDR) at 'A' and Short-term IDR at 'F1'. The Outlook on the Long-term IDR is Stable. The operating environment for traditional investment managers (IMs) remains favourable, driven by improved global equity markets that have increased assets under management (AUM) and attracted investor flows. This has resulted in
LONDON - Aberdeen Asset Management, a leading investor in drugmaker AstraZeneca, said on Monday that U.S. group Pfizer had room to improve its 55-pounds-per-share offer for its British rival.
LONDON, May 19 - Aberdeen Asset Management, a leading investor in drugmaker AstraZeneca, said on Monday that U.S. group Pfizer had room to improve its 55-pounds-per-share offer for its British rival.
Earnings vs. Estimates
Analyst Research Reports
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: Thomson Reuters Stock Report
Aberdeen Asset Management PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.